View ValuationBio-Gate 향후 성장Future 기준 점검 1/6Bio-Gate의 수익이 증가할 것으로 예상됨입니다.핵심 정보n/a이익 성장률n/aEPS 성장률Chemicals 이익 성장42.1%매출 성장률15.6%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트19 Mar 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공지 • Aug 07Bio-Gate AG, Annual General Meeting, Sep 12, 2025Bio-Gate AG, Annual General Meeting, Sep 12, 2025, at 10:00 W. Europe Standard Time.New Risk • Sep 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€1.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.2m free cash flow). Earnings have declined by 18% per year over the past 5 years. Market cap is less than US$10m (€8.22m market cap, or US$9.06m). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (10.0% increase in shares outstanding).공지 • May 09Bio-Gate AG, Annual General Meeting, Jun 14, 2024Bio-Gate AG, Annual General Meeting, Jun 14, 2024, at 10:00 W. Europe Standard Time.Reported Earnings • May 05Full year 2023 earnings releasedFull year 2023 results: Revenue: €7.48m (up 22% from FY 2022). Net loss: €1.62m (loss narrowed 10% from FY 2022). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany.New Risk • Mar 28New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.24m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.3m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 16% per year over the past 5 years. Market cap is less than US$10m (€9.24m market cap, or US$9.97m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding).New Risk • Mar 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.3m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 16% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (€10.4m market cap, or US$11.4m).New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€2.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.3m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 16% per year over the past 5 years. Market cap is less than US$10m (€8.49m market cap, or US$9.20m). Minor Risk Shareholders have been diluted in the past year (10.0% increase in shares outstanding).New Risk • Aug 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.74m (US$9.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (€8.74m market cap, or US$9.48m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€2.6m). Shareholders have been diluted in the past year (10.0% increase in shares outstanding).Reported Earnings • Sep 08First half 2022 earnings released: EPS: €0 (vs €0.01 loss in 1H 2021)First half 2022 results: EPS: €0. Revenue: €2.75m (down 13% from 1H 2021). Net loss: €1.06m (loss widened €990.0k from 1H 2021). Revenue is forecast to grow 28% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat.Reported Earnings • Apr 08Full year 2021 earnings releasedFull year 2021 results: Revenue: €6.52m (up 26% from FY 2020). Net loss: €544.1k (loss narrowed 32% from FY 2020). Over the next year, revenue is forecast to grow 17%, compared to a 8.9% growth forecast for the industry in Germany.이익 및 매출 성장 예측DB:BIG1 - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202811N/A1N/A112/31/20279N/A0N/A112/31/20268N/A0N/A112/31/20257N/A-1N/A16/30/20257-1-1-1N/A3/31/20257-1-1-1N/A12/31/20247-2-1-1N/A9/30/20247-2-1-1N/A6/30/20248-2-1-1N/A3/31/20247-2-1-1N/A12/31/20237-2-1-1N/A9/30/20237-2-2-2N/A6/30/20237-1-2-2N/A3/31/20236-2-2-2N/A12/31/20226-2-3-2N/A9/30/20226-2-2-1N/A6/30/20226-2-1-1N/A3/31/20226-1-1-1N/A12/31/20216-1-1-1N/A9/30/20216-1-1-1N/A6/30/20216-1-2-1N/A3/31/20216-1-1-1N/A12/31/20205-1-1-1N/A9/30/20205-1-1-1N/A6/30/20205-1-1-1N/A3/31/20204-1-1-1N/A12/31/20194-1-1-1N/A9/30/20193-1-1-1N/A6/30/20193-1-1-1N/A3/31/20194-1N/A-1N/A12/31/20184-1N/A-1N/A9/30/20184-1N/A0N/A6/30/201850N/A0N/A3/31/201840N/A0N/A12/31/201740N/A0N/A9/30/201740N/A0N/A6/30/201740N/A0N/A3/31/201740N/A0N/A12/31/201640N/A0N/A9/30/201640N/A0N/A6/30/201640N/A0N/A3/31/201630N/A0N/A12/31/20153-1N/A0N/A9/30/20153-1N/A0N/A6/30/20153-1N/A0N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: BIG1 의 예상 수익 증가율이 절약률(1.9%)보다 높은지 판단하기에는 데이터가 부족합니다.수익 vs 시장: BIG1 의 수익이 German 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 수익: BIG1 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.수익 대 시장: BIG1 의 수익(연간 15.6%)이 German 시장(연간 6.4%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: BIG1 의 수익(연간 15.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: BIG1의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/06 07:39종가2026/05/06 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Bio-Gate AG는 2명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Cosmin FilkerGBC AGMatthias GreiffenbergerGBC AG
공지 • Aug 07Bio-Gate AG, Annual General Meeting, Sep 12, 2025Bio-Gate AG, Annual General Meeting, Sep 12, 2025, at 10:00 W. Europe Standard Time.
New Risk • Sep 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€1.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.2m free cash flow). Earnings have declined by 18% per year over the past 5 years. Market cap is less than US$10m (€8.22m market cap, or US$9.06m). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (10.0% increase in shares outstanding).
공지 • May 09Bio-Gate AG, Annual General Meeting, Jun 14, 2024Bio-Gate AG, Annual General Meeting, Jun 14, 2024, at 10:00 W. Europe Standard Time.
Reported Earnings • May 05Full year 2023 earnings releasedFull year 2023 results: Revenue: €7.48m (up 22% from FY 2022). Net loss: €1.62m (loss narrowed 10% from FY 2022). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany.
New Risk • Mar 28New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.24m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.3m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 16% per year over the past 5 years. Market cap is less than US$10m (€9.24m market cap, or US$9.97m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding).
New Risk • Mar 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.3m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 16% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (€10.4m market cap, or US$11.4m).
New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€2.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.3m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 16% per year over the past 5 years. Market cap is less than US$10m (€8.49m market cap, or US$9.20m). Minor Risk Shareholders have been diluted in the past year (10.0% increase in shares outstanding).
New Risk • Aug 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.74m (US$9.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (€8.74m market cap, or US$9.48m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€2.6m). Shareholders have been diluted in the past year (10.0% increase in shares outstanding).
Reported Earnings • Sep 08First half 2022 earnings released: EPS: €0 (vs €0.01 loss in 1H 2021)First half 2022 results: EPS: €0. Revenue: €2.75m (down 13% from 1H 2021). Net loss: €1.06m (loss widened €990.0k from 1H 2021). Revenue is forecast to grow 28% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat.
Reported Earnings • Apr 08Full year 2021 earnings releasedFull year 2021 results: Revenue: €6.52m (up 26% from FY 2020). Net loss: €544.1k (loss narrowed 32% from FY 2020). Over the next year, revenue is forecast to grow 17%, compared to a 8.9% growth forecast for the industry in Germany.